Dupilumab在荷兰BioDay注册研究中治疗难治性特应性皮炎52周长期有效性
52周时EASI评分平均改善76.6%,70.3%患者达到EASI-75,最常见不良事件为结膜炎(34%),仅8.1%停药。
要点
- Dupilumab治疗难治性特应性皮炎52周EASI评分平均改善76.6%。
- 52周时70.3%患者达到EASI-75,高于16周时的59.9%。
- 结膜炎最常见(34%),仅8.1%患者停药。
核心结论
- Dupilumab治疗难治性成人特应性皮炎在52周内持续改善临床结局,且安全性可接受。
主要发现
- 第16周EASI评分平均变化为-70.0%(标准差33.2%),第52周进一步降至-76.6%(标准差30.6%)。
- 第16周59.9%患者达到EASI-75,第52周70.3%达到EASI-75。
- 最常见不良事件为结膜炎(34%),17例(8.1%)患者停用Dupilumab。
临床怎么用
- 对于难治性成人特应性皮炎,Dupilumab可作为长期治疗选择,需关注结膜炎等不良事件。
局限性
- 因缺乏对照组和观察性设计,可能存在偏倚因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited. OBJECTIVE: To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis. METHODS: Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated. RESULTS: Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was -70.0% (standard deviation 33.2%) and further decreased to -76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment. LIMITATIONS: Because of the lack of a control group and observational design, factors of bias may have been induced. CONCLUSION: Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.
引用
- Ariëns LFM, van der Schaft J, Spekhorst LS, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. J Am Acad Dermatol. 2020. PMID: 32946967. doi:10.1016/j.jaad.2020.08.127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。